TP-252

**TP-252** is a **small molecule drug**, specifically a chemically stable, magnesium L-lysinate bis-eicosapentaenoate salt derivative of **eicosapentaenoic acid (EPA)**, an omega-3 polyunsaturated fatty acid, designed to deliver high plasma levels of **EPA free fatty acid (EPA-FFA)**. Developed by **Thetis Pharmaceuticals LLC**, it acts as an **immunomodulator** rather than an immunosuppressant, balancing immune responses by reducing proinflammatory ω-6 eicosanoids (e.g., arachidonic acid-derived PGE2, 5-HETE) and increasing anti-inflammatory ω-3 eicosanoids (e.g., EPA, DHA metabolites like PGE3, 14-HDoHE) in colonic mucosa. It shows preclinical efficacy in reducing intestinal tumor number/size in **Apc** mouse/rat models of familial adenomatous polyposis (**FAP**) and is positioned as adjunct therapy to 5-ASA for **ulcerative colitis (UC)** remission maintenance and to standard care for delaying colectomy in adolescent **FAP** patients; it has **FDA Orphan Drug Designation** for **FAP** (Adenomatous Polyposis Coli) and is at **Phase 2** (pending).

Other names

EPA free fatty acid derivativeEPA-FFA derivativeEicosapentaenoic acid free fatty acid derivativemagnesium l-lysinate bis-eicosapentaenoate